LLY

866.19

+3.49%↑

UNH

516.46

+0.12%↑

ABBV

209.03

-0.39%↓

NVO

75.31

-1.89%↓

AZN

74.07

-1.16%↓

LLY

866.19

+3.49%↑

UNH

516.46

+0.12%↑

ABBV

209.03

-0.39%↓

NVO

75.31

-1.89%↓

AZN

74.07

-1.16%↓

LLY

866.19

+3.49%↑

UNH

516.46

+0.12%↑

ABBV

209.03

-0.39%↓

NVO

75.31

-1.89%↓

AZN

74.07

-1.16%↓

LLY

866.19

+3.49%↑

UNH

516.46

+0.12%↑

ABBV

209.03

-0.39%↓

NVO

75.31

-1.89%↓

AZN

74.07

-1.16%↓

LLY

866.19

+3.49%↑

UNH

516.46

+0.12%↑

ABBV

209.03

-0.39%↓

NVO

75.31

-1.89%↓

AZN

74.07

-1.16%↓

Search

Johnson and Johnson

Chiusa

SettoreSettore sanitario

163.28 -0.06

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

162.34

Massimo

164.36

Metriche Chiave

By Trading Economics

Entrata

3.4B

Vendite

20M

23B

P/E

Media del settore

28.076

71.874

EPS

2.04

Rendimento da dividendi

3.05

Margine di Profitto

15.235

Dipendenti

138,100

EBITDA

652M

5.9B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+2.84% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.05%

3.03%

Utili prossimi

15 apr 2025

Prossima data del' Ex Dividendo

19 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

25B

392B

Apertura precedente

163.34

Chiusura precedente

163.28

Notizie sul Sentiment di mercato

By Acuity

37%

63%

97 / 387 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Johnson and Johnson Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 mar 2025, 15:16 UTC

I principali Market Mover

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10 mar 2025, 13:59 UTC

I principali Market Mover

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

21 mar 2025, 23:02 UTC

Acquisizioni, Fusioni, Takeovers

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21 mar 2025, 13:35 UTC

Utili
Azioni calde

Stocks to Watch Friday: J&J, Nike, FedEx, Micron -- WSJ

14 mar 2025, 09:30 UTC

Notizie principali

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

7 mar 2025, 01:00 UTC

Notizie principali

Finance Executives Seek Stability Amid Erratic Tariff Shifts -- WSJ

18 feb 2025, 22:22 UTC

Notizie principali

Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan -- Update

14 feb 2025, 13:00 UTC

Notizie principali

J&J's High Hopes for Heart-Rhythm Device Grounded by Safety Concerns -- WSJ

24 gen 2025, 07:00 UTC

Notizie principali

Disasters Spawn New Businesses. The California Wildfires Will Do the Same. -- Barrons.com

22 gen 2025, 21:39 UTC

Utili

These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 gen 2025, 19:41 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 gen 2025, 17:38 UTC

Discorsi di Mercato
Utili

J&J's Forex Headwind in Outlook Surprised Investors -- Market Talk

22 gen 2025, 16:48 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More -- Barrons.com

22 gen 2025, 14:51 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Ford, and More -- Barrons.com

22 gen 2025, 14:09 UTC

Notizie principali
Utili

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 gen 2025, 13:04 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Travelers, and More -- Barrons.com

22 gen 2025, 12:47 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Oracle, Nvidia, J&J, Procter & Gamble, United, Agilysys, and More -- Barrons.com

22 gen 2025, 12:34 UTC

Utili

Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Light -- IBD

22 gen 2025, 12:15 UTC

Discorsi di Mercato

J&J's 2025 Sales View Misses Wall Street Estimates -- Market Talk

22 gen 2025, 11:57 UTC

Discorsi di Mercato
Utili

J&J 4Q Sales Rise on Demand for Cancer Drugs, Medical Devices -- Market Talk

22 gen 2025, 11:30 UTC

Utili

J&J's Earnings Beat Estimates But Guidance Is Mixed -- MarketWatch

22 gen 2025, 11:23 UTC

Notizie principali
Utili

J&J Reports Strong Revenue and Profit But Faces Challenges in 2025 -- WSJ

22 gen 2025, 11:22 UTC

Notizie principali
Utili

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 gen 2025, 11:20 UTC

Utili

Johnson & Johnson: Innovative Medicine 4Q Results Driven by In-Market Portfolio and Continued Uptake From Recently Launched Products, With 10 Brands Growing Double Digits >JNJ

22 gen 2025, 11:20 UTC

Utili

Johnson & Johnson 4Q Worldwide MedTech Sales $8.19B >JNJ

22 gen 2025, 11:20 UTC

Utili

Johnson & Johnson 4Q U.S. Sales $13.20B >JNJ

22 gen 2025, 11:20 UTC

Utili

Johnson & Johnson: MedTech Business, With Addition of Shockwave Medical, Delivered Operational Sales Growth of 7.6% in 4Q >JNJ

22 gen 2025, 11:20 UTC

Utili

Johnson & Johnson Sees 2025 Operational Sales of $90.9B-$91.7B >JNJ

22 gen 2025, 11:20 UTC

Utili

Johnson & Johnson Sees 2025 Adjusted Operational EPS $10.75-$10.95 >JNJ

22 gen 2025, 11:20 UTC

Utili

Johnson & Johnson Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

Confronto tra pari

Modifica del prezzo

Johnson and Johnson Previsione

Obiettivo di Prezzo

By TipRanks

2.84% in crescita

Previsioni per 12 mesi

Media 168.27 USD  2.84%

Alto 185 USD

Basso 152 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Johnson and Johnson - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

5

Acquista

8

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

162.85 / 164.7Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

97 / 387 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.